News & Videos - PROTALIX BIOTHERAPEUTICS

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results PR Newswire CARMIEL, Israel, March 14, 2024 Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , March 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression...

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 PR Newswire CARMIEL, Israel, March 7, 2024 Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , March 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based protein...

Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference PR Newswire CARMIEL, Israel, Feb. 23, 2024 Corporate presentation scheduled for Monday, February 26, 2024 at 1:00 PM ET CARMIEL, Israel , Feb. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell based protein...

Protalix BioTherapeutics Issues 2024 Letter to Stockholders PR Newswire CARMIEL, Israel, Dec. 26, 2023 CARMIEL, Israel , Dec. 26, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer,...

Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results PR Newswire CARMIEL, Israel, Nov. 6, 2023 Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel , Nov. 6, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression...

Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023 PR Newswire CARMIEL, Israel, Oct. 30, 2023 Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel , Oct. 30, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based...

Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel PR Newswire CARMIEL, Israel, Oct. 9, 2023 CARMIEL, Israel , Oct. 9, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today issued the following statement by Dror Bashan , Protalix's...

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors PR Newswire CARMIEL, Israel, Sept. 12, 2023 Appointment effective as of September 14, 2023; Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel , Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary...

Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire CARMIEL, Israel, Sept. 6, 2023 CARMIEL, Israel , Sept. 6, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based protein expression system, today announced that Dror Bashan , the...

Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results PR Newswire CARMIEL, Israel, Aug. 7, 2023 Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , Aug. 7, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression...

Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference PR Newswire CARMIEL, Israel, Aug. 1, 2023 CARMIEL, Israel , Aug. 1, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based protein expression system, today announced that Dror Bashan , the Company's...

Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023 PR Newswire CARMIEL, Israel, July 31, 2023 Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , July 31, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based...

Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease PR Newswire CARMIEL, Israel, June 8, 2023 Event will take place on Tuesday, June 27, 2023 in New York CARMIEL, Israel , June 8, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins...

Protalix BioTherapeutics Issues Letter to Stockholders PR Newswire CARMIEL, Israel, May 30, 2023 CARMIEL, Israel , May 30, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror...

Protalix BioTherapeutics set to join Russell 3000® Index PR Newswire CARMIEL, Israel, May 23, 2023 CARMIEL, Israel , May 23, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based protein expression system, today announced that it is set to join the broad-market Russell 3000 ® Index at the...

Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases PR Newswire CARMIEL, Israel, May 18, 2023 Milestone payment triggered by FDA approval of ELFABRIO ® (pegunigalsidase alfa-iwxj) and payable within 30 days of approval CARMIEL, Israel , May 18, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced...

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease PR Newswire BOSTON and CARMIEL, Israel, May 10, 2023 - PEGylated enzyme replacement therapy designed to provide long half-life* - BOSTON and CARMIEL, Israel , May 10, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare...

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease PR Newswire PARMA, Italy, BOSTON and CARMIEL, Israel, May 5, 2023 - PEGylated enzyme replacement therapy designed to provide a long half-life - PARMA, Italy , BOSTON and CARMIEL, Israel , May 5, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and...

Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results PR Newswire CARMIEL, Israel, May 4, 2023 Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , May 4, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system,...

Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023 PR Newswire CARMIEL, Israel, April 27, 2023 Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , April 27, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein...